论文部分内容阅读
[目的]探讨肝细胞生长因子受体(c-Met)可溶性形式(sMet)在鼻咽癌患者血浆中的水平变化及临床意义。[方法]收集84例鼻咽癌患者和84名正常人的血浆标本,ELISA检测血浆中sMet水平,并以ROC曲线评价sMet水平对鼻咽癌发生风险的临床预测价值。[结果]鼻咽癌Ⅰ～Ⅱ期患者血浆中sMet的水平[(293.6±15.8)ng/ml]及鼻咽癌Ⅲ～Ⅳ期患者血浆中sMet的水平[(343.8±12.6)ng/ml]分别为正常对照组表达水平[(224.2±13.5)ng/ml]的1.31、1.53倍(P<0.01)。ROC曲线分析显示,血浆sMet水平和发生鼻咽癌的风险存在密切相关性,具有明显的临床诊断价值。[结论]sMet可能是鼻咽癌早期诊断的一个潜在的血浆标志物。
[Objective] To investigate the changes and clinical significance of soluble form of hepatocyte growth factor receptor (c-Met) in plasma of patients with nasopharyngeal carcinoma. [Methods] The plasma samples from 84 patients with nasopharyngeal carcinoma and 84 normal individuals were collected. The levels of sMet in plasma were detected by ELISA, and the clinical predictive value of sMet levels for the risk of nasopharyngeal carcinoma was evaluated by ROC curve. [Results] The plasma levels of sMet in patients with stage Ⅰ ~ Ⅱ nasopharyngeal carcinoma [(293.6 ± 15.8) ng / ml] and the levels of sMet in patients with stage Ⅲ ~ Ⅳ nasopharyngeal carcinoma [(343.8 ± 12.6) ng / ml] Respectively, 1.31 and 1.53 folds (P <0.01) of the normal control group [(224.2 ± 13.5) ng / ml], respectively. ROC curve analysis showed that plasma sMet levels and the risk of occurrence of nasopharyngeal carcinoma are closely related, with obvious clinical diagnostic value. [Conclusion] sMet may be a potential plasma marker for the early diagnosis of nasopharyngeal carcinoma.